Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Alnylam
Alnylam
3 Hurdles Ahead of Alnylam and Its Revolutionary New Drug
Motley Fool
Wed, 08/15/18 - 10:13 pm
Alnylam
Onpattro
RNAi
After Alnylam’s solo maiden launch, here comes the tricky bit
EP Vantage
Tue, 08/14/18 - 12:06 am
Alnylam
drug launches
FDA
RNAi
Patisiran
Onpattro
Alnylam Prices First Gene Silencing Drug At $450,000 Per Patient, But Offers Money-Back Guarantee
Forbes
Sun, 08/12/18 - 01:19 pm
Alnylam
FDA
drug pricing
hATTR amyloidosis
Onpattro
In first, FDA approves RNA interference drug from Alnylam
Biopharma Dive
Fri, 08/10/18 - 02:25 pm
Alnylam
RNAi
FDA
Patisiran
Onpattro
hATTR amyloidosis
With patisiran launch in its sights, Alnylam plots a major hiring spree
Fierce Pharma
Tue, 08/7/18 - 12:02 pm
Alnylam
Patisiran
RNAi
hirings
Alnylam Pharmaceuticals Is "Launch Ready"
Motley Fool
Mon, 08/6/18 - 11:51 pm
Alnylam
FDA
Onpattro
TTRsc02
lumasiran
The Week Ahead In Biotech: Conferences, PDUFA Dates And IPOs
Yahoo/Benzinga
Sun, 08/5/18 - 07:25 pm
biotech
IPOs
Pain Therapeutics
Remoxy
Vertex Pharmaceuticals
lumacaftor/ivacaftor
Alnylam
Patisiran
Regeneron
Eylea
Insmed
Paratek
Vaccinex
The UK's MHRA Grants Early Access to Anlylam's Patisiran
CP Wire
Fri, 08/3/18 - 09:23 am
Alnylam
Patisiran
hATTR amyloidosis
UK
The UK's MHRA Grants Early Access to Anlylam's Patisiran
Fri, 08/3/18 - 09:01 am
Alnylam
Patisiran
hATTR amyloidosis
Alnylam Receives Positive CHMP Opinion for Hereditary Amyloidosis Treatment
CP Wire
Fri, 07/27/18 - 10:22 am
Alnylam
Patisiran
EMA
hATTR amyloidosis
Alnylam Receives Positive CHMP Opinion for Hereditary Amyloidosis Treatment
Fri, 07/27/18 - 10:01 am
Alnylam
Patisiran
hATTR amyloidosis
Alnylam Presents Ph III results of Patisiran in Hereditary ATTR (hATTR) Amyloidosis
CP Wire
Mon, 07/23/18 - 09:42 am
Alnylam
Patisiran
hereditary ATTR amyloidosis
Alnylam Presents Ph III results of Patisiran in Hereditary ATTR (hATTR) Amyloidosis
Mon, 07/23/18 - 09:40 am
Alnylam
hereditary ATTR amyloidosis
Patisiran
Poised to launch its first marketing effort, Alnylam makes a big leap into CNS diseases and Alzheimer’s
Endpoints
Tue, 05/8/18 - 08:22 pm
Alnylam
RNAi
Alzheimer's disease
FDA Extends Action Date on Akcea's Inotersen, Alnylam Now in Lead
CP Wire
Fri, 05/4/18 - 09:58 am
Akcea
hereditary ATTR amyloidosis
FDA
inotersen
Alnylam
Patisiran
FDA Extends Action Date on Akcea's Inotersen, Alnylam Now in Lead
Fri, 05/4/18 - 09:54 am
Akcea Therapeutics
inotersen
Alnylam
Patisiran
Alnylam and FDA Agree on Primary Endpoint for Lumasiran in Primary Hyperoxaluria Type 1 Study
CP Wire
Thu, 05/3/18 - 11:34 am
Alnylam
lumasiran
Primary Hyperoxaluria
Alnylam and FDA Agree on Primary Endpoint for Lumasiran in Primary Hyperoxaluria Type 1 Study
Thu, 05/3/18 - 11:12 am
Alnylam
lumasiran
Primary Hyperoxaluria
EU Advisory Group Backs Orphan Drug Designation for Alnylam's ALN-TTRsc02 for ATTR Amyloidosis
CP Wire
Mon, 04/23/18 - 11:01 am
Alnylam
EMA
orphan drugs
ALN-TTRsc02
ATTR amyloidosis
EU Advisory Group Backs Orphan Drug Designation for Alnylam's ALN-TTRsc02 for ATTR Amyloidosis
Mon, 04/23/18 - 09:37 am
Alnylam
amyloidosis
ALN-TTRsc02
Pages
« first
‹ previous
…
3
4
5
6
7
8
9
10
11
…
next ›
last »